R&G PharmaStudies Co. Ltd. A (301333) — Cash Flow Quality Index
R&G PharmaStudies Co. Ltd. A (301333) has a Cash Flow Quality Index of 1.19x as of June 2022. Operating cash flow of CN¥40.98 Million exceeds net income of CN¥34.56 Million, indicating high earnings quality where cash backs reported profits. Explore 301333 cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
R&G PharmaStudies Co. Ltd. A Cash Flow Quality Index (2019–2025)
Historical Cash Flow Quality Index for R&G PharmaStudies Co. Ltd. A across 7 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check R&G PharmaStudies Co. Ltd. A (301333) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for R&G PharmaStudies Co. Ltd. A (2019–2025)
Year-by-year earnings quality comparison for R&G PharmaStudies Co. Ltd. A. For live market cap and the full company financial profile, see R&G PharmaStudies Co. Ltd. A market cap and net worth.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.83x | CN¥114.20 Million | CN¥136.90 Million | ▼ -24.4% |
| 2024 | 1.10x | CN¥154.76 Million | CN¥140.22 Million | ▼ -6.8% |
| 2023 | 1.18x | CN¥192.56 Million | CN¥162.53 Million | ▲ +3.2% |
| 2022 | 1.15x | CN¥130.47 Million | CN¥113.59 Million | ▼ -0.5% |
| 2021 | 1.15x | CN¥114.57 Million | CN¥99.24 Million | ▲ +119.5% |
| 2020 | 0.53x | CN¥44.10 Million | CN¥83.84 Million | ▼ -58.0% |
| 2019 | 1.25x | CN¥103.48 Million | CN¥82.63 Million | — |